Barrett’s esophagus (BE) is an acquired pre-malignant condition that is the result of chronic damage to the esophagus mucosa caused by reflux. Gastroesophageal reflux disease (GERD) and BE are major risks factors for esophageal adenocarcinoma. Effective treatment for BE should control GERD symptoms but these patients frequently presents with other associated conditions that makes management more challenging. Laparoscopic antireflux surgery (LARS), restoring the gastroesophageal barrier, is a very effective treatment of patients with BE, but its role in cancer prevention remain controversial. There is strong evidence that surgery can promote regression, but less so for reducing progression. The aim of this article was to review the current role of antireflux surgery in preventing progression to dysplasia or cancer in patients with BE and GERD.
SpechlerSJSouzaRF. Barrett’s esophagus. N Engl J Med. 2014;371(9):836-845.
2.
SpechlerSJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA. 2013;310:627-636.
3.
SpechlerSJSharmaPSouzaRFInadomiJMShaheenNJ. American Gastroenterological Association technical review on the management of Barrett’s esophagus. Gastroenterology. 2011;140(3):e18-e52.
4.
DrewitzDJSamplinerREGarewalHS. The incidence of adenocarcinoma in Barrett’s esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997;92:212-215.
5.
LagergrenJBergstromRLindgrenANyrenO. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. New Engl J Med. 1999;340:825-831.
6.
SchlemperRJRiddellRHKatoY, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47:251-255.
7.
Hvid-JensenFPedersenLDrewesAMSørensenHTFunch-JensenP. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375-1383.
8.
BhatSColemanHGYousefF, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049-1057.
9.
OelschlagerBKBarrecaMChangLOleynikovDPellegriniCA. Clinical and pathologic response of Barrett’s esophagus to laparoscopic antireflux surgery. Ann Surg. 2003;238(4):458-456.
10.
DeMeesterTR. Surgical therapy for Barrett’s esophagus: prevention, protection and excision. Dis Esophagus. 2002;15(2):109-116.
11.
Ouatu-LascarRFitzgeraldRCTriadafilopoulosG. Differentiation and proliferation in Barrett’s esophagus and the effects of acid suppression. Gastroenterology. 1999;117:327-335.
12.
El-SeragHBAguirreTVDavisS, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol. 2004;99:1877-1883.
13.
HuoXJuergensSZhangX, et al. Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett’s epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011;301:G278-G286.
14.
VelaMFCamacho-LobatoLSrinivasanRTutuianRKatzPOCastellDO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001;120(7):1599-1606.
15.
GersonLBBoparaiVUllahNTriadafilopoulosG. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett’s oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther. 2004;20(6):637-643.
16.
PetersFTGaneshSKuipersEJ, et al. Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study. Gut. 1999;45(4):489-494.
17.
SinghPTaylorRHColin-JonesDG. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett’s metaplasia is present. Am J Gastroenterol. 1994;89:349-356.
18.
ChampionGRichterJEVaeziMFSinghSAlexanderR. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett’s esophagus. Gastroenterology. 1994;107:747-754.
19.
AttwoodSELundellLHatlebakkJG, et al. Medical or surgical management of GERD patients with Barrett’s esophagus: the LOTUS trial 3-year experience. J Gastrointest Surg. 2008;12:1646-1654.
20.
DeMeesterSR. Barrett’s oesophagus: treatment with surgery. Best Pract Res Clin Gastroenterol. 2015;29(1):211-217.
21.
ChangEYMorrisCDSeltmanAK, et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review. Ann Surg. 2007;246(1):11-21.
22.
WassenaarEBOelschlagerBK. Effect of medical and surgical treatment of Barrett’s metaplasia. World J Gastroenterol. 2010;16(30): 3773-3779.
23.
HofstetterWLPetersJHDeMeesterTR, et al. Long-term outcome of antireflux surgery in patients with Barrett’s esophagus. Ann Surg. 2001;234(4):532-539.
24.
DesaiKMSoperNJFrisellaMM, et al. Efficacy of laparoscopic antireflux surgery in patients with Barrett’s esophagus. Am J Surg. 2003;186:652-659.
25.
MorrowEBushyheadDWassenaarE, et al. The impact of laparoscopic anti-reflux surgery in patients with Barrett’s esophagus. Surg Endosc. 2014;28(12):3279-3284.
26.
Sharma FalkGWWestonAPRekerDJohnstonMSamplinerRE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4(5):566-572.
27.
WetscherGJGadenstaetterMKlinglerPJ, et al. Efficacy of medical therapy and antireflux surgery to prevent Barrett’s metaplasia in patients with gastroesophageal reflux disease. Ann Surg. 2001;234(5):627-632.
28.
ParrillaPMartinez de HaroLFOrtizAMunitizVMolinaJBermejoJ, et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus. Ann Surg. 2003;237(3):291-298.
29.
YeWChowWHLagergrenJYinLNyrénO. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology. 2001;121(6):1286-1289.
30.
CoreyKESchmitzSMShaheenNJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett’s esophagus? A meta-analysis. Am J Gastroenterol2003;98(11):2390-2394.
31.
BowersSPMattarSGSmithCDWaringJPHunterJG. Clinical and histologic follow-up after antireflux surgery for Barrett’s esophagus. J Gastrointest Surg. 2002;6(4):532-538; discussion 539.
32.
ZehetnerJDeMeesterSRAyaziS, et al. Long-term follow-up after anti-reflux surgery in patients with Barrett’s esophagus. J Gastrointest Surg. 2010;14(10):1483-1491.
33.
NadaletoBFHerbellaFAPattiMG. Gastroesophageal reflux disease in the obese: pathophysiology and treatment. Surgery. 2016;159(2):475-486.
34.
KindelTLOleynikovD. The improvement of gastroesophageal reflux disease and Barrett’s after bariatric surgery. Obes Surg. 2016;26(4):718-720.
35.
CsendesABraghetoIBurdilesPSmokGHenriquezAParadaF. Regression of intestinal metaplasia to cardiac or fundic mucosa in patients with Barrett’s esophagus submitted to vagotomy, partial gastrectomy and duodenal diversion. A prospective study of 78 patients with more than 5 years of follow up. Surgery. 2006;139(1):46-53.
36.
CsendesABraghettoIBurdilesPSmokGHenríquezABurgosAM. Late Results of the Surgical Treatment of 125 Patients with Short-Segment Barrett Esophagus. Arch Surg. 2009;144(10):921-927.
